(E)-2-hydroxy-N'-(1-(2-hydroxyphenyl)ethylidene)benzohydrazide
|
|
(E)-2-hydroxy-N'-(1-(2-hydroxyphenyl)ethylidene)benzohydrazide 속성
- 밀도
- 1.24±0.1 g/cm3(Predicted)
- 저장 조건
- -20°C
- 용해도
- DMF:1.0(Max Conc. mg/mL);3.7(Max Conc. mM)
DMSO:1.0(Max Conc. mg/mL);3.7(Max Conc. mM)
- 물리적 상태
- 가루
- 산도 계수 (pKa)
- 8.27±0.35(Predicted)
- 색상
- 흰색에서 베이지색
안전
- 위험 및 안전 성명
- 위험 및 사전주의 사항 (GHS)
| 그림문자(GHS): |
|
|||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 신호 어: | Warning | |||||||||||||||||||||
| 유해·위험 문구: |
|
|||||||||||||||||||||
| 예방조치문구: |
|
(E)-2-hydroxy-N'-(1-(2-hydroxyphenyl)ethylidene)benzohydrazide C화학적 특성, 용도, 생산
용도
2-Hydroxy-benzoic Acid [1-(2-Hydroxyphenyl)ethylidene]hydrazide is a GTPase-activating protein (SH3 domain)-binding protein 2 (G3BP2) inhibitor. G3BP2 is involved with breast tumor initiation.Biochem/physiol Actions
C108 is a small molecule that exhibits cancer-selective cytotoxicity (Viability = 100%/MCF-10A vs. 50%/BT-474, 67%/4T1, 70%/MDA-MB-231 & MDA-MB-453 post 48 h 1 μM C108 treatment) and synergizes with low dose paclitaxel in reducing ALDH-positive tumor-initiating cells (TIC poulation = 56.6%/control, 60.6%/0.1 μM paclitaxel alone, 47.4%/1 μM C108 alone, 7.3%/combined treatment for 24 h in BT474 breast cancer cultures) by targeting stress granule-associated protein G3BP2 (GAP SH3 domain-binding protein 2). Likewise, C108 pretreatment prior to xenografting greatly reduces BT-474 tumor-initiating frequency (from 1/175 to 1/1103 by limiting dilution xenograft assays) in mice in vivo. G3BP2 is reported to bind and stabilize SART3 mRNA, thereby indirectly regulating the core pluripotency transcription factors Oct-4 and Nanog critically involved in ESC self-renewal and breast tumor initiation.(E)-2-hydroxy-N'-(1-(2-hydroxyphenyl)ethylidene)benzohydrazide 준비 용품 및 원자재
원자재
준비 용품
(E)-2-hydroxy-N'-(1-(2-hydroxyphenyl)ethylidene)benzohydrazide 공급 업체
글로벌( 19)공급 업체
| 공급자 | 전화 | 이메일 | 국가 | 제품 수 | 이점 |
|---|---|---|---|---|---|
| Aladdin Scientific | +1-833-552-7181 |
sales@aladdinsci.com | United States | 52927 | 58 |
| Sigma-Aldrich | 021-61415566 800-8193336 |
orderCN@merckgroup.com | China | 51471 | 80 |
| Tianjin Kailiqi Biotechnology Co., Ltd. | 15076683720 |
klq@cw-bio.com | China | 3501 | 55 |
| Shanghai Hongye Biotechnology Co. Ltd | 400-9205774 |
sales@glpbio.cn | China | 6870 | 58 |
| ChemeGen(Shanghai) Biotechnology Co.,Ltd. | 18818260767 |
sales@chemegen.com | China | 11289 | 58 |
| Energy Chemical | 021-58432009 400-005-6266 |
marketing1@energy-chemical.com | China | 44894 | 58 |
| Shanghai Universal Biotech Co.,Ltd | 18768175414 |
gaojun@univ-bio.com | China | 24998 | 58 |
| TargetMol Chemicals Inc. | 4008200310 |
marketing@tsbiochem.com | China | 24023 | 58 |
| Shaoguan Qicheng Biotechnology Co., Ltd | 18122215013 |
780229652@qq.com | China | 939 | 58 |
| Nanjing Tengyi Biotechnology Co., Ltd | 025-58851786 17714337195 |
sales@tybiochem.com | China | 5021 | 58 |